4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $57,018 | -35.9% | 4,479 | -9.0% | 0.04% | -34.0% |
| Q2 2023 | $88,959 | +25.0% | 4,923 | +18.9% | 0.05% | +35.9% |
| Q1 2023 | $71,167 | -44.1% | 4,140 | -27.8% | 0.04% | -40.9% |
| Q4 2022 | $127,286 | +9.7% | 5,731 | -25.4% | 0.07% | +26.9% |
| Q1 2022 | $116,000 | -35.2% | 7,683 | -5.6% | 0.05% | -23.5% |
| Q4 2021 | $179,000 | -8.7% | 8,140 | +12.2% | 0.07% | -20.9% |
| Q3 2021 | $196,000 | +6.5% | 7,257 | -5.0% | 0.09% | +13.2% |
| Q2 2021 | $184,000 | – | 7,642 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 4,007,413 | $68,887,429 | 2.52% |
| Opaleye Management Inc. | 314,000 | $5,397,660 | 1.62% |
| Deep Track Capital, LP | 2,278,107 | $39,160,659 | 1.61% |
| Casdin Capital, LLC | 1,070,000 | $18,393,300 | 1.52% |
| Eagle Health Investments LP | 437,911 | $7,527,690 | 1.46% |
| ACUTA CAPITAL PARTNERS, LLC | 104,753 | $1,800,704 | 1.33% |
| Octagon Capital Advisors LP | 499,996 | $8,594,931 | 1.24% |
| Soleus Capital Management, L.P. | 469,400 | $8,068,986 | 0.84% |
| Novo Holdings A/S | 700,000 | $12,033,000 | 0.79% |
| VIKING GLOBAL INVESTORS LP | 3,937,914 | $67,692,742 | 0.32% |